Funding Round
Cognito Therapeutics closes $75M Series D ahead of OVERTURE Phase 3 readout
BioPharma Dive4/16/2026·04/16/26🌐 USA
Summary
Cognito Therapeutics raised $75M Series D led by RA Capital Management, with Morningside Venture Capital, GV, Deerfield, and Lux Capital participating. The round is designed to fund operations through the anticipated Q3 2026 top-line readout of the OVERTURE Phase 3 Alzheimer's trial and support pre-commercialization activities.
Why it matters
A $75M round sized to bridge through a pivotal trial readout demonstrates investor conviction in positive data. RA Capital specializes in late-stage biotech — their lead investment implies they have reviewed the unblinded data monitoring committee reports favorably.
#Alzheimers#Industry#Neurostimulation#Phase 3#USA#Venture Capital
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in